Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options
placeholder image
Publications in VIVO
 
    Export Publications Table
co-author
Co-author Network
map of science
Map of Science

Lode, H. N.

share the uri
  • Publications
scroll to property group menus

Publications

recent publications

  • academic article

    • Zeng, Y., Huebener, N., Fest, S., Weixler, S., Schroeder, U., Gaedicke, G., Xiang, R., Schramm, A., Eggert, A., Reisfeld, R. A., Lode, H. N. Fractalkine (cx3cl1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by t cells and natural killer cells Cancer Research  2007 67:2331-2338  DOI:10.1158/0008-5472.can-06-3041  PMID:17332365
    • Zeng, Y., Jiang, J., Huebener, N., Wenkel, J., Gaedicke, G., Xiang, R., Lode, H. N. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted il-2 Cancer Letters  2005 228:187-193  DOI:10.1016/j.canlet.2005.01.057  PMID:15953676
    • Niethammer, A. G., Wodrich, H., Loeffler, M., Lode, H. N., Emmerich, K., Abdollahi, A., Krempien, R., Debus, J., Huber, P. E., Reisfeld, R. A. Multidrug resistance-1 (mdr-1): A new target for t cell-based immunotherapy FASEB Journal  2005 19:158-159  DOI:10.1096/fj.04-2355fje  PMID:15498893
    • Neal, Z. C., Yang, J. C., Rakhmilevich, A. L., Buhtoiarov, I. N., Lum, H. E., Imboden, M., Hank, J. A., Lode, H. N., Reisfeld, R. A., Gillies, S. D., Sondel, P. M. Enhanced activity of hu14.18-il2 immunocytokine against murine nxs2 neuroblastoma when combined with interleukin 2 therapy Clinical Cancer Research  2004 10:4839-4847  DOI:10.1158/1078-0432.ccr-03-0799  PMID:15269160
    • Neal, Z. C., Imboden, M., Rakhmilevich, A. L., Kim, K. M., Hank, J. A., Surfus, J., Dixon, J. R., Lode, H. N., Reisfeld, R. A., Gillies, S. D., Sondel, P. M. Nxs2 murine neuroblastomas express increased levels of mhc class i antigens upon recurrence following nk-dependent immunotherapy Cancer Immunology Immunotherapy  2004 53:41-52  DOI:10.1007/s00262-003-0435-2  PMID:14504825
    • Schroeder, U., Bernt, K. M., Lange, B., Wenkel, J., Jikai, J., Shabat, D., Amir, R., Huebener, N., Niethammer, A. G., Hagemeier, C., Wiebusch, L., Gaedicke, G., et al. Hydrolytically activated etoposide prodrugs inhibit mdr-1 function and eradicate established mr-1 multidrug-resistant t-cell leukemia Blood  2003 102:246-253  DOI:10.1182/blood-2002-07-2268  PMID:12623853
    • Pertl, U., Wodrich, H., Ruehlmann, J. M., Gillies, S. D., Lode, H. N., Reisfeld, R. A. Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma Blood  2003 101:649-654  DOI:10.1182/blood-2002-02-0391  PMID:12393580
    • Wrasidlo, W., Gaedicke, G., Guy, R. K., Renaud, J., Pitsinos, E., Nicolaou, K. C., Reisfeld, R. A., Lode, H. N. A novel 2 '-(n-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models Bioconjugate Chemistry  2002 13:1093-1099  DOI:10.1021/bc0200226  PMID:12236791
    • Xiang, R., Primus, F. J., Ruehlmann, J. M., Niethammer, A. G., Silletti, S., Lode, H. N., Dolman, C. S., Gillies, S. D., Reisfeld, R. A. A dual-function DNA vaccine encoding carcinoembryonic antigen and cd40 ligand trimer induces t cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice Journal of Immunology  2001 167:4560-4565  PMID:11591784
    • Niethammer, A. G., Xiang, R., Ruehlmann, J. M., Lode, H. N., Dolman, C. S., Gillies, S. D., Reisfeld, R. A. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma Cancer Research  2001 61:6178-6184  PMID:11507070
    • Shabat, D., Lode, H. N., Pertl, U., Reisfeld, R. A., Rader, C., Lerner, R. A., Barbas, C. F. In vivo activity in a catalytic antibody-prodrug system: antibody catalyzed etoposide prodrug activation for selective chemotherapy Proceedings of the National Academy of Sciences of the United States of America  2001 98:7528-7533  DOI:10.1073/pnas.131187998  PMID:11404472  PMCID:PMC34702
    • Pertl, U., Luster, A. D., Varki, N. M., Homann, D., Gaedicke, G., Reisfeld, R. A., Lode, H. N. Ifn-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific cd8 t cell response induced by single-chain il-12 gene therapy Journal of Immunology  2001 166:6944-6951  PMID:11359856
    • Xiang, R., Silletti, S., Lode, H. N., Dolman, C. S., Ruehlmann, J. M., Niethammer, A. G., Pertl, U., Gillies, S. D., Primus, F. J., Reisfeld, R. A. Protective immunity against human carcinoembryonic antigen (cea) induced by an oral DNA vaccine in cea-transgenic mice Clinical Cancer Research  2001 7:856S-864S  PMID:11300483
    • Lode, H. N., Pertl, U., Xiang, R., Gaedicke, G., Reisfeld, R. A. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma Medical and Pediatric Oncology  2000 35:641-646  DOI:10.1002/1096-911x(20001201)35:6<641::aid-mpo34>3.0.co;2-r  PMID:11107137
    • Balicki, D., Reisfeld, R. A., Pertl, U., Beutler, E., Lode, H. N. Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma Proceedings of the National Academy of Sciences of the United States of America  2000 97:11500-11504  DOI:10.1073/pnas.210382997  PMID:11016973  PMCID:PMC17229
    • Lode, H. N., Xiang, R., Pertl, U., Forster, E., Schoenberger, S. P., Gillies, S. D., Reisfeld, R. A. Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction Journal of Clinical Investigation  2000 105:1623-1630  DOI:10.1172/jci9177  PMID:10841521  PMCID:PMC300854
    • Lode, H. N., Xiang, R., Perri, P., Pertl, U., Lode, A., Gillies, S. D., Reisfeld, R. A. What to do with targeted il-2 Drugs of Today  2000 36:321-336  PMID:12861355
    • Xiang, R., Lode, H. N., Chao, T. H., Ruehlmann, J. M., Dolman, C. S., Rodriguez, F., Whitton, J. L., Overwijk, W. W., Restifo, N. P., Reisfeld, R. A. An autologous oral DNA vaccine protects against murine melanoma Proceedings of the National Academy of Sciences of the United States of America  2000 97:5492-5497  DOI:10.1073/pnas.090097697  PMID:10779556  PMCID:PMC25856
    • Lode, H. N., Reisfeld, R. A. Targeted cytokines for cancer immunotherapy Immunologic Research  2000 21:279-288  DOI:10.1385/ir:21:2-3:279  PMID:10852128
    • Xiang, R., Lode, H. N., Gillies, S. D., Reisfeld, R. A. T cell memory against colon carcinoma is long-lived absence of antigen Journal of Immunology  1999 163:3676-3683  PMID:10490962
    • Lode, H. N., Xiang, R., Duncan, S. R., Theofilopoulos, A. N., Gillies, S. D., Reisfeld, R. A. Tumor-targeted il-2 amplifies t cell-mediated immune response induced by gene therapy with single-chain il-12 Proceedings of the National Academy of Sciences of the United States of America  1999 96:8591-8596  DOI:10.1073/pnas.96.15.8591  PMID:10411920
    • Lode, H. N., Moehler, T., Xiang, R., Jonczyk, A., Gillies, S. D., Cheresh, D. A., Reisfeld, R. A. Synergy between an antiangiogenic integrin alpha(v) antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases Proceedings of the National Academy of Sciences of the United States of America  1999 96:1591-1596  DOI:10.1073/pnas.96.4.1591  PMID:9990069
    • Lode, H. N., Xiang, R., Becker, J. C., Gillies, S. D., Reisfeld, R. A. Immunocytokines: A promising approach to cancer immunotherapy Pharmacology & Therapeutics  1998 80:277-292  DOI:10.1016/s0163-7258(98)00033-3  PMID:9888698
    • Dolman, C. S., Mueller, B. M., Lode, H. N., Xiang, R., Gillies, S. D., Reisfeld, R. A. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy Clinical Cancer Research  1998 4:2551-2557  PMID:9796990
    • Xiang, R., Lode, H. N., Dreier, T., Gillies, S. D., Reisfeld, R. A. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases Cancer Research  1998 58:3918-3925  PMID:9731503
    • Pertl, U., Xiang, R., Kleindienst, P., Becker, J. C., Gillies, S. D., Reisfeld, R. A., Lode, H. N. Tumor targeting with immunocytokines. A novel approach for cancer therapy Minerva Biotecnologica  1998 10:89-99
    • Lode, H. N., Reisfeld, R. A., Handgretinger, R., Nicolaou, K. C., Gaedicke, G., Wrasidlo, W. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(i)(1) effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma Cancer Research  1998 58:2925-2928  PMID:9679947
    • Dreier, T., Lode, H. N., Xiang, R., Dolman, C. S., Reisfeld, R. A., Kang, A. S. Recombinant immunocytokines targeting the mouse transferrin receptor: Construction and biological activities Bioconjugate Chemistry  1998 9:482-489  DOI:10.1021/bc980020e  PMID:9667950
    • Lode, H. N., Dreier, T., Xiang, R., Varki, N. M., Kang, A. S., Reisfeld, R. A. Gene therapy with a single chain interleukin 12 fusion protein induces t cell-dependent protective immunity in a syngeneic model of murine neuroblastoma Proceedings of the National Academy of Sciences of the United States of America  1998 95:2475-2480  DOI:10.1073/pnas.95.5.2475  PMID:9482910
    • Lode, H. N., Xiang, R., Dreier, T., Varki, N. M., Gillies, S. D., Reisfeld, R. A. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy Blood  1998 91:1706-1715  PMID:9473237
    • Lode, H. N., Xiang, R., Varki, N. M., Dolman, C. S., Gillies, S. D., Reisfeld, R. A. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow Journal of the National Cancer Institute  1997 89:1586-1594  DOI:10.1093/jnci/89.21.1586  PMID:9362156
    • Xiang, R., Lode, H. N., Dolman, C. S., Dreier, T., Varki, N. M., Qian, X. Q., Lo, K. M., Lan, Y., Super, M., Gillies, S. D., Reisfeld, R. A. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy Cancer Research  1997 57:4948-4955  PMID:9354462

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support